Rubius Therapeutics, Inc. - RUBY STOCK NEWS

Rubius Therapeutics announced preclinical data for RTX-321, a therapy targeting HPV 16-positive cancers, published in Nature Communications. This off-the-shelf product candidate has shown potential in activating specific T cell responses and broad immune stimulation. The Phase 1 clinical trial is currently enrolling patients with advanced HPV 16-related cancers. Significant preclinical findings suggest RTX-321 could induce a durable immune response, addressing the critical need for effective treatments in this space. Initial clinical results are expected in Q1 2022.

Rubius Therapeutics announced promising initial results from its Phase 1/2 trial of RTX-240 for advanced solid tumors, highlighting single-agent activity and favorable safety. The trial showed no Grade 3/4 adverse events, with two partial responses observed. Rubius is advancing clinical trials for RTX-240 in relapsed/refractory acute myeloid leukemia (AML) and RTX-321 for HPV 16-positive cancers. The company expects multiple data milestones in 2021, supported by a strong balance sheet.

Rubius Therapeutics (Nasdaq: RUBY) announced plans to report its first-quarter financial results on May 10, 2021, before market open. The company specializes in Red Cell Therapeutics™ aimed at treating cancer and autoimmune diseases. Their proprietary RED PLATFORM® allows for the genetic engineering of red blood cells, enhancing their therapy's potential. Notably, the company will not hold a teleconference to discuss these results following the release.

Rubius Therapeutics (Nasdaq:RUBY) has initiated dosing in a Phase 1 clinical trial for RTX-321, targeting HPV 16-positive cancers. This novel therapy operates as an allogeneic, off-the-shelf Red Cell Therapeutic, designed to enhance T cell responses and activate immune systems. The trial focuses on patients with advanced, unresectable HPV 16-positive cancers, including cervical and head and neck cancers. Positive preclinical results suggest RTX-321 could generate effective immune responses, offering hope for patients with limited treatment options.

Rubius Therapeutics (Nasdaq:RUBY) presented initial clinical results for RTX-240 at the AACR Annual Meeting, demonstrating its ability to activate the immune system in patients with advanced solid tumors. Promising safety data and clinical responses were noted. The company plans to continue patient enrollment and present further results by year-end. Additionally, it aims to explore RTX-240's combination with anti-PD-1 therapy and select specific tumor types for Phase 2 expansion. This investigational therapy could represent a significant advance in treating previously treated cancer patients.

Rubius Therapeutics (NASDAQ: RUBY) announced an upsized underwritten public offering of 6,896,552 shares at $29.00 each, aiming to raise approximately $200 million. The offering is expected to close by March 19, 2021, pending customary conditions. The funds will support the advancement of clinical programs and technology development, with any remaining proceeds allocated to R&D and general corporate purposes, including operating expenses and capital expenditures related to its manufacturing facility.

Rubius Therapeutics (NASDAQ: RUBY) announced a public offering of $150 million of common stock, with a 30-day option for underwriters to purchase an additional 15%. Proceeds will support clinical program developments and R&D, alongside general corporate needs. The offering is still subject to market conditions and will be conducted under an SEC-approved shelf registration statement. J.P. Morgan, Jefferies, and Guggenheim Securities are the joint bookrunning managers for this offering.

Rubius Therapeutics (Nasdaq:RUBY) reported promising initial data from its Phase 1/2 clinical trial of RTX-240 in patients with metastatic anal cancer and uveal melanoma. Results showed a confirmed partial response in one patient with a 54% reduction in target lesions, and an unconfirmed partial response in another patient. No drug-related Grade 3/4 adverse events were observed, with only mild toxicities reported. The company aims to expand the trial and optimize dosing, with milestones including further clinical results and new trial arms planned for 2022.

Rubius Therapeutics (Nasdaq: RUBY) announced plans for a press release and webcast on March 15, 2021, detailing initial clinical data from its Phase 1/2 trial of RTX-240, targeting advanced solid tumors. The call, set for 8:00 a.m. EDT, will provide insights into the progress of its innovative Red Cell Therapeutics™. This treatment aims to leverage engineered red blood cells to address cancer and autoimmune diseases.